



**Clover Corporation Limited**

ABN 85 003 622 866

**ASX ANNOUNCEMENT**

**18<sup>th</sup> March 2022**

## **Clinical research shows improvement in IQ of premature infants**

- **Clover's proprietary High DHA emulsion improves cognitive outcomes in premature infants.**

18<sup>th</sup> March 2022, Clover Corporation (ASX:CLV), a science-based Bioactives company developing novel nutritional applications of Docosahexaenoic Acid (DHA), today announced the release of new results from the clinical research study called the N3RO trial. Clover has been informed by the responsible researchers at the South Australian Health and Medical Research Institute (SAHMRI), of results from the randomised, double-blinded controlled clinical trial, where the potential benefits of its high DHA emulsion for supporting normal cognitive development of premature infants was assessed.

Premature babies generally have a lower IQ than full term babies. Early indications, as reported by SAHMRI, are that the clinical research study has achieved a statistically significant 3.5 point IQ score improvement in the high DHA emulsion treatment group of the 656 Australian premature babies assessed at 5 years of age, when compared with the group that received the placebo emulsion. The final results will be available when the full report is compiled, where further analysis of these results will determine next steps for the program.

Infants born before 29 weeks of gestational age were enrolled in the N3RO trial. Clover's proprietary emulsion high in the omega3 fatty acid DHA was administered to half of these babies as a supplement to their nutrition, along with standard treatments currently considered optimal for their successful development. The rest of the group received a placebo emulsion in replacement for the DHA emulsion. A variety of parameters indicating the health and development of the treated infants were measured.

The N3RO trial follows on from positive outcomes in a previous Phase III trial named DINO, (DHA for the Improvement of Neurodevelopmental Outcome) in which Preterm infants whose diet was supplemented with higher DHA showed improved cognitive development in girls at 18 months, reduced oxygen requirement at 36 weeks in boys and reduced incidence of hay fever later in their development. The N3RO clinical research study commenced in 2012 after receiving funding support from the National Health and Medical Research Council

and product support from Clover Corporation. Over the course of the project, Clover Corporation has invested \$1.235M in product development, professional services and people.

"We are encouraged in this early report of the top-line results from the study. We remain committed to better understanding the full data set as we consider potential paths forward for the DHA emulsion product," said Peter Davey, CEO & Managing Director of Clover Corporation. "With strong clinical results from the previous DINO study and high tolerability of the DHA formulation we will continue to seek a viable path forward for the development of DHA emulsions in this and wider clinical applications."

Clover Corporation's core business remains the manufacture and sale of encapsulated Omega 3 and 6 oils supplied as ingredients into food, pharmaceutical and infant formula products. Recent regulations in the European Union and pending changes to China legislation for Chinese sold infant formula provide opportunities for additional growth in the future. This will be supported by the development of new products and relationships to expand available markets and applications of Clover's microencapsulated oil products.

Clover released its half year results on 16 March 2022, which can be accessed through the following link: <https://www.clovercorp.com.au/en/invest-our-business/asx-announcements/>

**For further information, please contact:**

Mr Rupert Harrington – Chairman, Clover Corporation +61 3 8347 5000

Mr Peter Davey – MD & CEO, Clover Corporation +61 3 8347 5000

**About Clover Corporation Limited**

Clover Corporation is an Australian company listed on the Australian Stock Exchange (ASX:CLV). Clover evolved from being a research and development, manufacturing, and marketing company to one concentrating on forming strategic relationships focused on technology, new product development and commercialisation.

Clover's superior microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods, and beverages. Developed through extensive research and development, our proprietary technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. All Clover products reach the highest standards of purity, stability, and performance, allowing customers to maximise and deliver nutrition.

For more information about Clover visit [www.clovercorp.com.au](http://www.clovercorp.com.au)